Caribou Biosciences' high P/S ratio, despite expected revenu...
Caribou Biosciences' high P/S ratio, despite expected revenue slump and industry's predicted 250% growth, may worry investors. A potential disappointment awaits if the P/S aligns with the negative growth outlook.
There's Reason For Concern Over Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Massive 25% Price Jump
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment